Neuronoff

Executive Summary

Neuronoff is a US-based medical device company pioneering a novel approach to neuromodulation for chronic pain. Founded in 2017 and headquartered in Cleveland, the company has developed the Injectrode, a minimally invasive electrode that can be injected through a needle into target nerves, eliminating the need for surgical implantation. This technology aims to transform chronic pain management by making neuromodulation therapy accessible in standard clinical settings, potentially reducing costs, recovery time, and procedural risks. The Injectrode is designed to provide long-lasting pain relief by delivering electrical stimulation to peripheral nerves, offering an alternative to opioids and invasive spinal cord stimulators. With an estimated $4 billion addressable market in the US alone, Neuronoff's platform could disrupt the neuromodulation landscape if clinical and regulatory milestones are met. To date, Neuronoff has demonstrated proof-of-concept in preclinical studies and early human feasibility trials. The company's technology has garnered interest from key opinion leaders in pain management and neuromodulation. While still in the development stage, Neuronoff has the potential to capture significant market share if it can achieve regulatory approval and establish clinical efficacy in larger trials. The next few years are critical as the company advances through clinical development and seeks strategic partnerships or funding to support commercialization. Key risks include regulatory hurdles, competition from established players, and the need to demonstrate long-term safety and efficacy. Nonetheless, the Injectrode's differentiation as a minimally invasive, reversible, and low-cost solution positions it as a promising candidate in the chronic pain treatment paradigm.

Upcoming Catalysts (preview)

• TBDFDA IDE approval for pivotal clinical trial70% success
• TBDCompletion of first-in-human study results80% success
• TBDStrategic partnership or licensing deal with a major medical device company50% success